Department of Medicine and Surgery, GEMMAIR Research Group, Tarragona Joan XXIII University Hospital, Pere Virgili Health Research Institute (IISPV), Rovira i Virgili University (URV), Spain
*Corresponding author:Joanna Michalina Jurek, Department of Medicine and Surgery, GEMMAIR Research Group, Tarragona Joan XXIII University Hospital, Pere Virgili Health Research Institute (IISPV), Rovira i Virgili University (URV), C/ Dr. Mallafré Guasch, 4, 43005 Tarragona, Spain
Submission: September 04, 2024;Published: September 19, 2024
ISSN : 2578-0263Volume6 Issue5
Metabolic syndrome, characterized by at least three metabolic health alterations such as abdominal obesity, hypertension, low HDL-C, high fasting glucose, and hypertriglyceridemia, is associated with increased risks of type 2 diabetes and various vascular complications. This condition also elevates the risk of Breast Cancer (BC), particularly in postmenopausal women, by promoting systemic inflammation, hormonal imbalances, and vascular dysfunction, which collectively create an environment conducive to cancer progression and metastasis. Insulin and IGF-1 signalling pathways, often dysregulated in metabolic syndrome, play significant roles in BC development and recurrence by activating oncogenic pathways in neoplastic tissues. Epidemiological evidence strongly links metabolic complications to increased BC risk, particularly in patients with obesity, hypertension, and diabetes. This review paper discusses current evidence on the associations between metabolic syndrome, vascular complications, and BC risk, emphasizing the role of lifestyle interventions like exercise and the Mediterranean diet in restoring metabolic homeostasis and reducing BC risk. Additionally, impaired lipid metabolism, particularly hypercholesterolemia, is highlighted as a key contributor to BC pathogenesis, with statin therapy showing potential in reducing BC recurrence. Novel therapeutic strategies targeting vascular complications, such as the use of antiangiogenic agents like danthron, are explored for their potential in treating BC in patients with metabolic syndrome. These findings underscore the importance of integrated metabolic and oncological care to mitigate BC risk and improve outcomes in patients with metabolic syndrome.
Keywords:Breast cancer; Metabolic disease; Vascular health; Metastasis